- Notes from a peptide meetupWith an FDA advisory committee set to decide this week whether it recommends that several popular peptides be reclassified, I wanted to learn more. Cue a last-minute ticket purchase to ...Endpoints · 6d ago↗ source
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…BioSpace · 6d ago↗ source
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.<br>